Abstract:Abstract Background Little study investigates the association between baseline type 2 biomarker levels and clinical features in children diagnosed with asthma. Characterizing clinical remission in Th2-high asthma could offer valuable insights into asthma prognosis. Objectives The study aims to investigate the association of baseline type 2 biomarker levels and clinical features in children with asthma, and to identify predictors of clinical remission of asthma in children. Methods A total of 172 children with baseline age of 6.87 ± 3.04 (mean ± SD) years were enrolled in the study including 119 with physician-diagnosed asthma who regularly attended a pediatric asthma center and 53 control subjects with no respiratory symptoms. Clinical tests included lung function examination, Fraction of exhaled NO (FeNO), total IgE, blood eosinophil, and skin test. Serum Th2 biomarkers were examined by ELISA. The enrolled patients have readjusted into Th2-high asthma according to clinical eosinophil count and total IgE, and Th2-high asthma subjects were further classified into acute attack asthma, persistent asthma, and clinical remission according to the recent GINA guidelines and clinical evaluation. To verify our results, the concentration of TSLP levels was measured in BALF, serum, and lung tissue by ELISA in mouse models. Results Compared with asthma and control groups, eosinophil counts and blood eosinophils (%) were significant, whereas, no correlation was observed between asthma subjects and controls including Th2 biomarkers, gender, or ages. Positive correlations were observed between Th2 inflammatory biomarkers (TSLP, TRAC IL-5, IL-13, and Periostin) at baseline. Th2-high asthma (n = 110) was defined based on clinical measurement of IgE > 100 IU/ml and a blood eosinophil count ≥ 140 cells/µl. Among those Th2-high asthma subjects, there were 48 in acute exacerbation (43.6%), and 36 in clinical remission (32.7%), 26 were clinical asthma persistence (23.6%). Lung function and serum TSLP had marked significance among the three categories. Compared with clinical remission asthmatic subjects and controls, serum TSLP levels were significantly higher in subjects experiencing acute exacerbation and subjects defined as asthma persistence. Spearman’s correlation outlined that serum TSLP levels were related to Total IgE (IU/mL), FEV1/FVC ratio, and FEF25-75, pred %. Multivariate logistic regression analysis demonstrated that serum TSLP levels were associated with clinical remission in Th2-high asthma children (OR = 1.009; 95% CI, 1.0087–1.0086 P = 0.023<0.05). It is also revealed that serum TSLP levels may help evaluate clinical remission in Th2-high asthma when using ROC curves analysis (AUC = 0.5887, 95% CI: 0.5052 to 0.7038, P < 0.05). A cutoff value of 373.363 pg/mL was found with the highest clinical sensitivity and specificity. PPV, and NPV were 100%, 39.1%, and 59.4%, 100% in two groups, respectively. However, there were no positive results in the analysis of multivariable logistic regression in determining the predictors of persistence in Th2-high asthma. In BALF mouse, TSLP concentration had no statistically significant change in the acute and remission stages when compared to the control, but it did increase noticeably in the chronic stage (P < 0.001).

Baseline Severity and Disease Duration Can Predict the Response to Allergen-specific Immunotherapy in Allergic Rhinitis

Predictors for Short-Term Efficacy of Allergen-Specific Sublingual Immunotherapy in Children with Allergic Rhinitis

Effects of Subcutaneous Immunotherapy in Allergic Rhinitis Children Sensitive to Dust Mites.

[The efficacy of sublingual specific immunotherapy in children with allergic rhinitis]

Predicting allergen immunotherapy efficacy based on early maintenance phase response in routine clinical practice

Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy

Prediction of sublingual immunotherapy efficacy in allergic rhinitis by serum metabolomics analysis

Effect of baseline serum vitamin D level on symptom and medication scores of subcutaneous immunotherapy in children with mite allergy

Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study

Effect of One-Year Subcutaneous and Sublingual Immunotherapy on Clinical and Laboratory Parameters in Children with Rhinitis and Asthma: A Randomized, Placebo-Controlled, Double-Blind, Double-Dummy Study

[LONGITUDINAL EVALUATION OF EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PEDIATRIC PERENNIAL ALLERGIC RHINITIS USING LABORATORY EXAMINATIONS AND IN VIVO BIOMARKERS]

Baseline Type 2 Biomarker Levels and Clinical Remission Predictors in Children with Asthma

Enhancing quality of life with 3-year course of sublingual immunotherapy for house dust mite-induced allergic rhinitis: An observational prospective study in real-life settings

Serum vitamin D3 deficiency can affect the efficacy of sublingual immunotherapy in children with allergic rhinitis: a retrospective cohort study

Leukotriene A4 Hydrolase Is a Candidate Predictive Biomarker for Successful Allergen Immunotherapy

Sublingual Tablet Immunotherapy Improves Quality of Life in Adults With Allergic Rhinoconjunctivitis

A meta-analysis investigating the efficacy and safety of allergen-specific immunotherapy in the management of respiratory allergies

Efficacy and safety of sublingual versus subcutaneous immunotherapy in children with allergic rhinitis: a systematic review and meta-analysis

Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy

[Evaluation of efficacy of 1 year after completing the 2-year specific sublingual immunotherapy treatment course in allergic rhinitis].

The early-phase transcriptome and the clinical efficacy analysis in three modes of subcutaneous immunotherapy for allergic rhinitis